Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

remove_circle_outline

Search Results (1)

Search Parameters:
Keywords = fetal methotrexate syndrome

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
6 pages, 1467 KiB  
Case Report
Distal Tibial Hemimelia in Fetal Methotrexate Syndrome: A Case Study and Literature Review
by Dae-Sik Jo and Seung-Hyun Lee
Children 2023, 10(2), 228; https://doi.org/10.3390/children10020228 - 27 Jan 2023
Cited by 1 | Viewed by 2247
Abstract
Methotrexate (MTX), a folate antagonist, is used in various fields, including malignancies and rheumatoid or inflammatory autoimmune diseases. MTX is used for the non-surgical treatment of ectopic pregnancies and the elective termination of pregnancy. The teratogenic effects of MTX have been recognized since [...] Read more.
Methotrexate (MTX), a folate antagonist, is used in various fields, including malignancies and rheumatoid or inflammatory autoimmune diseases. MTX is used for the non-surgical treatment of ectopic pregnancies and the elective termination of pregnancy. The teratogenic effects of MTX have been recognized since the 1960s. Fetal methotrexate syndrome (FMS) was established based on the study of congenital anomalies. Generally, there is a risk of FMS when MTX is used between four and six weeks after conception. Here, we reviewed the literature regarding MTX usage and described a case of FMS that was born with a rare anomaly, such as tibial hemimelia, in a mother who had received MTX 4 months before conception for the management of an ectopic pregnancy. Full article
(This article belongs to the Special Issue Neonatal Birth Defects: Latest Advances)
Show Figures

Figure 1

Back to TopTop